Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral 6R-BH4 dose-ranging placebo-controlled study in coronary artery disease
2005-006141-16Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Jul 2006
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sapropterin in coronary arteriosclerosis (3 arms), sponsored by University of Oxford. Primary endpoints: Brachial artery reactivity, Aortic distensibility and 2 more. Started Jul 2006; status: completed.
02
Drugs
sapropterin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2005-006141-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006141-16.